恆指午後曾挫逾400點 藥明康德及藥明生物跌幅擴至近8%-10%
恆指午後初段跌幅曾擴至411點或2.4%,低見16,550,考驗20天、10天及100天線(16,580-16,619)支持,現報16,639,跌321或1.9%,總成交額837億元。
藍籌股普遍下跌。美國生物技術創新組織(BIO)支持《生物安全法案》,藥明康德(02359.HK)及藥明生物(02269.HK)跌幅擴大,最低見41.15元及14.28元,現報41.4元及14.52元,續挫7.9%-9.7%。
三大藍籌內房及兩大物管股跌逾1%-4%,龍湖(00960.HK)沽壓最大,股價曾低見10.22元,現報10.44元,下挫4.4%。此外,恆隆地產(00101.HK)也回吐逾3%報8.61元。
內需股以李寧(02331.HK)、康師傅(00322.HK)及中升(00881.HK)沽壓最大,股價吐近4.5%-5%,報20.55元、8.93元及13.08元。
金融股以中國平安(02318.HK)及國壽(02628.HK)沽壓最大,股價均失守10天線,現報35.25元及9.43元,續跌3%-4%。績後友邦(01299.HK)續吐2.3%報60.8元,股價失守10天線。
騰訊(00700.HK)、京東(09618.HK)、百度(09888.HK)、阿里(09988.HK)及美團(03690.HK)跌逾2%-4.5%,後者沽壓最大,股價失守10天線(89.5元),午後曾低見87.1元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.